Alleviate Health, a company utilizing AI to streamline patient recruitment for clinical research sites, has officially launched its innovative product. The announcement comes alongside the successful completion of a $4.3 million seed funding round, prominently led by venture capital firm Andreessen Horowitz. This investment marks a step forward in enhancing the efficiency of clinical trials, an area that is critical for medical advancements.
The company already boasts partnerships with seven out of the fifteen leading site networks in the United States. Notable clients include Alcanza, CenExel, M3 Wake, Centricity, and Eximia. These partnerships highlight Alleviate’s growing impact in the marketplace as it seeks to address pressing challenges faced by clinical research sites.
Clinical research sites serve as the backbone of clinical trials, yet they often grapple with the overwhelming task of managing thousands of potential patients. Research staff must conduct calls to evaluate patient eligibility, qualify them against strict protocol criteria, and navigate the complexities of prescreening and scheduling. This labor-intensive process is often hindered by issues such as missed calls and inefficient workflows, leading to delays that can impede the progress of critical trials and cause burnout among research teams.
Alleviate Health is addressing this significant problem with a unique solution that leverages human-in-the-loop AI technology. These AI agents are available around the clock, engaging potential patients through SMS and voice communication. They verify patient eligibility against study protocols and facilitate the scheduling of visits and calls. By automating routine tasks, Alleviate allows human recruitment teams to focus on the moments that matter most, ensuring a necessary personal touch while drastically boosting overall efficiency.
All interactions, including patient preferences and medical information, are integrated into a clinical trial-specific customer relationship management (CRM) system. This system is uniquely designed to assist research sites in refining their future recruitment strategies, ultimately optimizing the entire recruitment process for clinical trials.
In its inaugural year of operation, Alleviate Health has successfully managed over 500,000 patient interactions across more than 190 clinical trial sites in both the United States and Canada. This ambitious effort has helped research sites accelerate their recruitment processes for over 300 distinct clinical trials.
In addition to support from Andreessen Horowitz, Alleviate has attracted investments from recognizable industry figures, including Jack Altman of Alt Capital and Ali Rowghani from First Harmonic. Other investors such as Sajith Wickramasekara of Benchling, Trey Holterman of Tennr, Josh Miller of Gradient Health, Max Cohen of Sprinter Health, and Christophe Rimann of Camber further underscore the confidence in Alleviate’s potential to innovate the clinical research landscape.
KEY QUOTES:
“Research sites are the backbone of every clinical trial. They deserve technology built specifically for their needs and the patients they serve.”
Saathvik Boompelli, CEO & Co-founder of Alleviate Health
“Our customers, who juggle dozens of trials at once, are now able to do more with less while delivering a truly seamless experience for patients.”
John Xu, CTO & Co-founder of Alleviate Health
“The impact that Alleviate has had on Alcanza’s recruitment function is incredible and one that I wouldn’t have believed when we first got started. Alleviate has enabled the scheduling of hundreds of on-site screening appointments not just at one site but at multiple sites across the entire Alcanza network during the past 10 months of working together.”
Carlos Orantes, CEO of Alcanza Clinical Research
“As the teams on the ground drive trials forward, research sites need modern tools, purpose-built to turn interest into enrolled patients. Alleviate gives research teams immense leverage – streamlining operations while improving the patient experience.”
Jay Rughani, investing partner at Andreessen Horowitz
